Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
201 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline landscape. Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS) or keratitis sicca, is a multifactorial disease of the tears and the ocular surface that results in discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. Symptoms include eye fatigue, sensitivity to light, eye redness and stringy mucus in or around eyes. Risk factors include age, having laser eye surgery and taking medications that can cause dry eyes. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 20, 9, 1, 24, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology). - The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Keratoconjunctivitis sicca (Dry Eye) - Overview 9 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Development 10 Pipeline Overview 10 Pipeline by Companies 11 Pipeline by Universities/Institutes 15 Products under Development by Companies 16 Products under Development by Universities/Institutes 20 Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment 21 Assessment by Target 21 Assessment by Mechanism of Action 24 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development 31 Alcon Laboratories Inc 31 Aldeyra Therapeutics Inc 31 Allergan Plc 31 Ascendia Pharmaceuticals LLC 32 BioLineRx Ltd 32 Cambium Medical Technologies LLC 33 Chong Kun Dang Pharmaceutical Corp 33 Clementia Pharmaceuticals Inc 34 Dompe Farmaceutici SpA 34 Elasmogen Ltd 34 HanAll Biopharma Co Ltd 35 Herantis Pharma Plc 35 Huons Global Co Ltd 36 InSite Vision Inc 36 Kala Pharmaceuticals Inc 37 KPI Therapeutics Inc 37 Kukje Pharmaceutical Industry Co Ltd 37 Laboratoires Thea SA 38 Lipicard Technologies Ltd 38 Merck & Co Inc 38 Mitotech SA 39 Nanomerics Ltd 39 Nemus Bioscience Inc 40 Novaliq GmbH 40 Ocular Therapeutix Inc 40 Oculis ehf 41 OncoNOx ApS 41 Otsuka Holdings Co Ltd 42 Quorum Innovations LLC 42 Redwood Pharma AB 43 RegeneRx Biopharmaceuticals Inc 43 Samjin Pharm Co Ltd 44 Santen Pharmaceutical Co Ltd 44 Seikagaku Corp 45 Shire Plc 45 Sun Pharma Advanced Research Company Ltd 46 Sylentis SAU 46 TearSolutions LLC 46 TopiVert Ltd 47 Vanda Pharmaceuticals Inc 47 Xigen SA 48 Keratoconjunctivitis sicca (Dry Eye) - Drug Profiles 49 ADP-355 - Drug Profile 49 ADP-399 - Drug Profile 50 ADX-102 - Drug Profile 51 ADX-103 - Drug Profile 57 AGN-223575 - Drug Profile 58 AGN-232411 - Drug Profile 59 AL-41A1 - Drug Profile 60 AVA-3486 - Drug Profile 61 AVX-012 - Drug Profile 62 AX-1606 - Drug Profile 63 BL-1230 - Drug Profile 64 BRM-421 - Drug Profile 65 cenegermin - Drug Profile 66 cinhyaluronate sodium - Drug Profile 69 Cis-Urocanic Acid - Drug Profile 70 cyclosporine - Drug Profile 72 cyclosporine - Drug Profile 75 cyclosporine - Drug Profile 77 cyclosporine - Drug Profile 78 cyclosporine - Drug Profile 79 cyclosporine - Drug Profile 80 cyclosporine - Drug Profile 81 cyclosporine SR - Drug Profile 82 dexamethasone acetate SR - Drug Profile 83 diclofenac sodium - Drug Profile 91 diquafosol tetrasodium - Drug Profile 92 Drug for Dry Eye - Drug Profile 94 ECF-843 - Drug Profile 95 Elate Ocular - Drug Profile 97 ELN-22 - Drug Profile 98 HL-036 - Drug Profile 99 HU-007 - Drug Profile 100 hyaluronate sodium - Drug Profile 101 ISV-101 - Drug Profile 102 K-089 - Drug Profile 103 KeraKlear - Drug Profile 104 KJ-14003 - Drug Profile 105 KJ-16001 - Drug Profile 106 KPI-190 - Drug Profile 107 Lacripep - Drug Profile 108 Leukothera - Drug Profile 109 lifitegrast - Drug Profile 111 LME-636 - Drug Profile 116 loteprednol etabonate - Drug Profile 117 LT-4003 - Drug Profile 120 NB-2222 - Drug Profile 121 Nov-03 - Drug Profile 122 Nov-07 - Drug Profile 123 OC-301 - Drug Profile 124 OCX-071 - Drug Profile 125 OTX-101 - Drug Profile 126 OX-1001 - Drug Profile 128 palovarotene - Drug Profile 129 plastoquinone decyl triphenylphosphonium bromide - Drug Profile 136 PPL-003 - Drug Profile 138 Protearin - Drug Profile 140 Qi-401 - Drug Profile 141 rebamipide - Drug Profile 142 RGN-259 - Drug Profile 144 RP-101 - Drug Profile 151 SA-001 - Drug Profile 153 SHP-659 - Drug Profile 154 SJP-002 - Drug Profile 156 solithromycin - Drug Profile 157 ST-266 - Drug Profile 171 Stem Cell Therapy for Cardiovascular, Central Nervous System, Mouth and Dental Disorders, Ophthalmology and Respiratory Disorders - Drug Profile 173 SYL-1001 - Drug Profile 175 tadekinig alfa - Drug Profile 177 TOP-1630 - Drug Profile 179 XG-104 - Drug Profile 181 zucapsaicin - Drug Profile 182 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects 184 Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products 188 Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones 189 Featured News & Press Releases 189 Appendix 196 Methodology 196 Coverage 196 Secondary Research 196 Primary Research 196 Expert Panel Validation 196 Contact Us 196 Disclaimer 197
List of Tables
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Alcon Laboratories Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by BioLineRx Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Cambium Medical Technologies LLC, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Clementia Pharmaceuticals Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici SpA, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Elasmogen Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Global Co Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea SA, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech SA, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nemus Bioscience Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Redwood Pharma AB, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharm Co Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corp, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sylentis SAU, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions LLC, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Vanda Pharmaceuticals Inc, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd..1), H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd..2), H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2017 (Contd..3), H2 2017 Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
